Last reviewed · How we verify
Ketotifen Fumarate 0.25% Cream
Ketotifen Fumarate 0.25% Cream is a Small molecule drug developed by Center for Vulvovaginal Disorders. It is currently in Phase 2 development.
At a glance
| Generic name | Ketotifen Fumarate 0.25% Cream |
|---|---|
| Sponsor | Center for Vulvovaginal Disorders |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketotifen Fumarate 0.25% Cream CI brief — competitive landscape report
- Ketotifen Fumarate 0.25% Cream updates RSS · CI watch RSS
- Center for Vulvovaginal Disorders portfolio CI
Frequently asked questions about Ketotifen Fumarate 0.25% Cream
What is Ketotifen Fumarate 0.25% Cream?
Ketotifen Fumarate 0.25% Cream is a Small molecule drug developed by Center for Vulvovaginal Disorders.
Who makes Ketotifen Fumarate 0.25% Cream?
Ketotifen Fumarate 0.25% Cream is developed by Center for Vulvovaginal Disorders (see full Center for Vulvovaginal Disorders pipeline at /company/center-for-vulvovaginal-disorders).
What development phase is Ketotifen Fumarate 0.25% Cream in?
Ketotifen Fumarate 0.25% Cream is in Phase 2.